Depomed Doses First Patient In Phase 3 Clinical Trial Of Gabapentin GR For Postherpetic Neuralgia Treatment - Quick Facts

(RTTNews) - Monday, Depomed, Inc. (DEPO | news | PowerRating | PR Charts ) announced that it dosed the first patient in a new pivotal registration Phase 3 clinical trial designed to evaluate the safety and efficacy of Gabapentin GR for the treatment of postherpetic neuralgia or PHN. Gabapentin GR is an investigational, extended release formulation of gabapentin, an FDA-approved product for PHN treatment.

Depomed said that the randomized, double-blind, placebo-controlled Phase 3 clinical trial will enroll approximately 450 patients with PHN, a persistent neuropathic pain condition caused by nerve damage after a shingles, or herpes zoster, viral infection.

Further, Depomed said that the primary objective of the study is to assess the efficacy of Gabapentin GR in reducing the pain associated with PHN, measured from baseline pain scores to the end of a ten-week stable treatment period, based on the Likert pain scale.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index